Literature DB >> 9274635

Treatment of acne with intermittent isotretinoin.

V Goulden1, S M Clark, C McGeown, W J Cunliffe.   

Abstract

Adults with acne represent an increasingly important population of acne sufferers referred for treatment. Acne, in these patients, is generally mild or moderate in severity but tends to be resistant to conventional antibiotic therapy. A study was carried out to assess the efficacy of intermittent moderate dose isotretinoin as a treatment for acne. Eighty consecutive patients, over the age of 25 years, referred with acne unresponsive to, or relapsing rapidly after three or more courses of conventional antibiotic therapy were recruited. Acne severity was assessed on the face, chest and back using the Leeds grading scale and the number of inflamed lesions was counted at the site showing the highest acne grade. The patients were 22 men and 58 women. The treatment regimen consisted of isotretinoin, 0.5 mg/kg per day for 1 week in every 4 week for a total period of 6 months. Seventy-five patients completed the study. The therapy was very well tolerated with mild cheilitis as the only side-effect. At the end of treatment, both total acne grade and lesion counts were significantly reduced (P < 0.0001). The acne had resolved in 68 (88%) patients. Twelve months after treatment, acne grades and inflamed lesion counts remained significantly improved (P < 0.0001) in the 68 patients who responded; however, 26 (39%) patients had relapsed. There was a significantly higher incidence of relapse in patients with predominantly truncal acne (P = 0.01). Patients who relapsed also had a significantly higher total acne grade, lesion count (P < 0.0001) and sebum excretion rate (P < 0.001) compared with those whose acne resolved. This study suggests that intermittent moderate dose isotretinoin may be a cost-effective alternative to full dose isotretinoin in a carefully selected group of adult patients with-acne. Selection criteria should include predominantly facial acne, total acne grade less than 1, inflamed lesion count less than 20 and sebum excretion rate less than 1.25 micrograms/cm2 per min.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9274635

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  14 in total

1.  The use of isotretinoin in acne.

Authors:  Alison Layton
Journal:  Dermatoendocrinol       Date:  2009-05

Review 2.  [Systemic acne therapy].

Authors:  A Thielitz; H Gollnick
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

3.  Severe generalised rhabdomyolysis with fatal outcome associated with isotretinoin.

Authors:  Benno Hartung; Hans F Merk; Wolfgang Huckenbeck; Thomas Daldrup; Eva Neuen-Jacob; Stefanie Ritz-Timme
Journal:  Int J Legal Med       Date:  2012-08-16       Impact factor: 2.686

4.  Concerns and awareness of acne patients about isotretinoin in qassim region of saudi arabia.

Authors:  Mana Al-Harbi
Journal:  Int J Health Sci (Qassim)       Date:  2010-01

Review 5.  Acne vulgaris.

Authors:  Sarah Purdy; David Deberker
Journal:  BMJ Clin Evid       Date:  2008-05-15

Review 6.  Not all acne is acne vulgaris.

Authors:  Harald P Gollnick; Christos C Zouboulis
Journal:  Dtsch Arztebl Int       Date:  2014-04-25       Impact factor: 5.594

7.  [Acne tarda. Acne in adults].

Authors:  T Jansen; O E Janßen; G Plewig
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

Review 8.  Acne vulgaris.

Authors:  Sarah Purdy; David de Berker
Journal:  BMJ Clin Evid       Date:  2011-01-05

9.  Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study.

Authors:  Ayse Akman; Cicek Durusoy; Meltem Senturk; Cilem Kaya Koc; Durali Soyturk; Erkan Alpsoy
Journal:  Arch Dermatol Res       Date:  2007-08-21       Impact factor: 3.017

10.  Safety and efficacy of low-dose isotretinoin in the treatment of moderate to severe acne vulgaris.

Authors:  Parinitha K Rao; Ramesh M Bhat; B Nandakishore; Sukumar Dandakeri; Jacintha Martis; Ganesh H Kamath
Journal:  Indian J Dermatol       Date:  2014-05       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.